RU EN

Mon.-Fri.: 1000-1900

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

«A.Zalesov & Partners» Patent & Law Firm is a full-service IP law firm that gives IP advice, handles litigation (patents, trademarks and designs) and provides services in patent, design and trademark prosecution in the Russian Patent and Trademark Office and the Eurasian Patent Office. We handle our international clients' patent and trademark portfolios (including Madrid and Hague Systems of trademark and design registration) in Russia as well as in the neighboring countries, including the countries of the Eurasian Custom and Economic Union. Twenty years of experience in conducting patent and trademark disputes between leading players in the relevant markets in Russia and abroad enables us to give verified practical advice on IP protection, invalidation and enforcement strategy.

 

In focus

Commentary by patent attorneys of «A.Zalesov & Partners» for the «Attorney’s Newspaper» on the decision to refuse to grant legal protection to the trademark of a Swedish company

On July 25, 2025, Russian IP Court issued a Decision supporting Rospatent's refusal to grant legal protection to the trademark of a Swedish company. Patent attorneys Anastasia Kiriukhina and Julia Kolomytseva commented on the Court's decision for the «Attorney’s Newspaper».

15.08.2025

Commentary by Anastasia Zalesova for the «Attorney’s Newspaper» on the Supreme Court's ruling in the case of a licensee's appeal of a know-how provision agreement

On July 25, 2025, the Supreme Court of the Russian Federation issued a ruling, explaining in which cases information provided under a license agreement is not a trade secret. Anastasia Zalesova commented on the ruling for Advokatskaya Gazeta.

15.08.2025

«A.Zalesov & Partners» achieved a decision to invalidate a Eurasian patent in full in the Russian Federation

The Board of the Chamber for Patent Disputes ruled in favor of the client of «A.Zalesov & Partners» in the case on opposition to the issuance of a patent for the use of pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of HER2-positive early-stage breast cancer.

15.08.2025